Transfusion-sparing hemostatic agents.
A variety of agents are available to improve hemostasis and reduce blood loss in multiple clinical settings. These agents are most commonly used to reduce bleeding when an underlying hemostatic defect is present. Some new agents offer the potential to decrease blood loss even in the absence of an obvious underlying hemostatic defect. The authors discuss the use of a variety of products to reduce bleeding and minimize transfusion of blood products in the setting of clotting factor deficiency or inhibition, platelet deficiency and/or dysfunction, increased fibrinolysis, therapeutic anticoagulation, and coagulopathies caused by dilution and consumption in the setting of trauma and surgery. The authors primarily focus on the available pharmaceuticals.
Chiu
Jason
J
SUNY-Buffalo, New York, USA.
Ketchum
Lloyd H
LH
Reid
Thomas J
TJ
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001458:Bandages; D001803:Blood Transfusion; D003029:Coagulants / Q000627:therapeutic use; D000075202:Contraindications; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006470:Hemorrhage / Q000517:prevention & control; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans
D000933:Antifibrinolytic Agents; D003029:Coagulants; D016298:Hematopoietic Cell Growth Factors